Hims & Hers Health Inc - Class A NYSE:HIMS Price, Chart, News & Insight

Hims & Hers Stock Falls 6.8% After Q2 Loss, Margin Pressure Offset Strong Revenue Growth

Hims & Hers Health (NYSE: HIMS) shares fell about 6.8% in after-hours trading after the company reported second-quarter 2026 results showing strong revenue and subscriber growth but significantly weaker profitability.

Revenue increased 38% year over year to $753.2 million, while subscribers rose 19% to nearly 2.9 million. Monthly revenue per average subscriber increased 21% to $92.

International expansion was a major growth driver. U.S. revenue increased 16% to $621.8 million, while rest-of-world revenue surged to $131.4 million from just $7.5 million a year earlier, helped by the June closing of the Eucalyptus acquisition.

Profitability Weighs on HIMS Stock

Despite the strong top-line performance, profitability deteriorated considerably. Gross margin fell to 64% from 76% a year earlier, while adjusted EBITDA declined to $60.3 million from $82.2 million.

Hims & Hers also swung to a net loss of $86.3 million from net income of $42.5 million in the year-ago quarter. Operating cash flow was negative $35.9 million, while free cash flow remained negative at $68.2 million.

These profitability and cash-flow figures likely explain the negative after-hours reaction despite accelerating revenue growth.

Hims & Hers Raises 2026 Revenue Guidance

The company raised its full-year revenue outlook to $3.1 billion-$3.3 billion and expects adjusted EBITDA of $275 million-$325 million, implying a 9%-10% margin.

For the third quarter, management expects revenue of $880 million-$900 million and adjusted EBITDA of $75 million-$95 million.

Management also highlighted continued investment in AI-driven healthcare services and expects domestic revenue growth to accelerate during the second half of 2026.

The 6.8% decline in HIMS shares suggests investors are focusing more heavily on the sharp gross-margin contraction, lower adjusted EBITDA and return to a GAAP loss than on the company's strong revenue growth and higher full-year sales outlook. The key issue ahead will be whether Hims & Hers can maintain its accelerating growth while restoring profitability as it expands internationally.

💬

Global Finance News 08-11-26

Hims & Hers (HIMS) Q1 2026: GLP-1 Pivot Crushes Margins, Stock Plunges 15% in Premarket

Hims & Hers is one of the most dramatic premarket movers today, down 15% after reporting a quarter that revealed the painful financial cost of its strategic pivot away from compounded semaglutide toward branded GLP-1 products. The top line held up. Everything below it did not.

The Revenue Miss and the Margin Collapse

Total revenue grew just 4% year-over-year to $608.1 million — a sharp deceleration from the triple-digit growth rates the company posted throughout 2025 when compounded semaglutide was driving explosive subscriber additions. More alarmingly, U.S. revenue actually fell 8% year-over-year to $529.9 million. The only reason total revenue grew at all is an extraordinary surge in international revenue — Rest of World revenue jumped 969% to $78.2 million, reflecting early traction in new markets including the pending Eucalyptus acquisition in Australia.

The margin story is worse. Gross margin collapsed to 65% from 73% a year ago — an 800 basis point deterioration driven by the shift toward branded GLP-1 products, which carry dramatically lower margins than compounded formulations. Adjusted EBITDA fell by more than half, to $44.3 million from $91.1 million. Net loss swung to $92.1 million from net income of $49.5 million a year ago. Monthly revenue per average subscriber declined 6% to $80, reflecting the mix shift toward lower-margin products.

The GLP-1 Transition: The Root Cause

The entire quarter can be explained by one word: semaglutide. Throughout most of 2025, Hims & Hers benefited from FDA enforcement discretion that allowed it to sell compounded semaglutide — a high-margin product that drove explosive revenue and subscriber growth. When the FDA ended that enforcement discretion following Novo Nordisk's restoration of Ozempic and Wegovy supply, Hims & Hers was forced to pivot to branded GLP-1 products. CFO Yemi Okupe acknowledged the strategic pivot explicitly, noting the company expanded its assortment of branded GLP-1 products in Q1 with early demand signals showing consumer reach broadening. But branded products mean lower margins, higher cost of goods, and a completely different unit economics profile. The market is repricing that reality this morning.

Subscribers grew 9% to nearly 2.6 million — showing the platform still has consumer pull — but the revenue per subscriber decline and margin compression suggest the economics of each new subscriber are structurally weaker than before.

Raised Revenue Guidance, But EBITDA Tells the Real Story

Hims & Hers raised full-year 2026 revenue guidance to $2.8 to $3.0 billion — a significant increase that reflects confidence in the international expansion and new category launches. Q2 revenue guidance of $680 to $700 million implies sequential acceleration. But the EBITDA picture tells a different story: full-year adjusted EBITDA guidance of $275 to $350 million implies a 10-12% margin for the full year, while Q2 EBITDA guidance of $35 to $55 million implies a 5-8% margin — a continued compression before any recovery. Free cash flow of $53 million was the one genuinely clean data point in the quarter, roughly flat year-over-year.

The Long-Term Vision vs. The Near-Term Pain

CEO Andrew Dudum struck a characteristically bullish tone, reaffirming 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, and positioning Hims & Hers as building toward the world's largest consumer health platform. The pending acquisition of Eucalyptus — an Australian digital health company — extends that international ambition and is excluded from current guidance. New investments in comprehensive diagnostics and technology infrastructure are being framed as the foundation for long-term competitive advantage and cost structure improvement.

💬

The Investor 05-12-26

Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform

Hims stock surged more than 40% Monday morning on news that Novo Nordisk will distribute its weight-loss drugs through the Hims platform.

(finance.yahoo.com)

💬

WS Investor 03-09-26

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus - TechStock²

(ts2.tech)

💬

WS News 12-31-25

Hims & Hers Launches 250 Million Dollars Share Buyback Program

Hims & Hers Health, Inc. authorized a new share repurchase program allowing the company to buy back up to 250 million dollars of its Class A common stock through November 11, 2028. Purchases may occur via open-market transactions, private deals, Rule 10b5-1 plans, or other methods, depending on market conditions.

The company also reported that between October 1 and November 7, 2025 it repurchased 1,334,572 shares for 55.5 million dollars, fully completing its previous 100 million dollars buyback program launched in July 2024.

💬

The Investor 11-17-25

Hims & Hers delivers 49% revenue growth and record profitability in Q3 2025

Hims & Hers Health (NYSE: HIMS) reported Q3 2025 revenue of nearly $600 million, up 49% year over year, with net income of approximately $16 million and record adjusted EBITDA exceeding $78 million, up 53%. The company’s subscriber base reached nearly 2.5 million, a 21% annual increase, reflecting growing demand for its personalized telehealth services. CEO Andrew Dudum emphasized expanding care offerings and partnerships as the platform evolves into a global health brand. CFO Yemi Okupe highlighted strong profitability and scaling efficiency, noting the company’s confidence in surpassing its long-term growth targets. Hims & Hers narrowed full-year 2025 guidance to $2.335–$2.355 billion in revenue and $307–$317 million in adjusted EBITDA.

💬

The Investor 11-04-25

Hims & Hers signs 15-year lease for major Ohio facility

Hims & Hers Health (NYSE: HIMS) announced it has entered into a 15-year lease for a 352,012-square-foot facility in New Albany, Ohio. The space will house offices, R&D, laboratories, manufacturing, and pharmaceutical dispensing.

Base rent begins April 1, 2026, at $5.98 million annually, with 3.25% yearly increases. The company will benefit from a rent abatement period until the start date and partial abatements for five months thereafter.
Hims provided a $5.98 million letter of credit from JPMorgan Chase as security and executed a guaranty backing lease obligations.

💬

The Investor 09-07-25

Hims & Hers Reports Q2 2025 Results: Revenue Jumps 73%, Net Income Hits $42.5M

Hims & Hers Health, Inc. (NYSE: HIMS) reported strong second quarter results, with revenue surging 73% year-over-year to $544.8 million. The company posted net income of $42.5 million and adjusted EBITDA of $82.2 million.

Subscriber count rose 31% to over 2.4 million, with monthly online revenue per subscriber up 30% to $74. The company reaffirmed full-year guidance of $2.3–2.4 billion in revenue and $295–335 million in adjusted EBITDA.

CEO Andrew Dudum highlighted growth momentum and expansion into new health specialties. CFO Yemi Okupe emphasized plans to enhance personalization, lab testing, and global reach.

💬

European Investor 08-05-25

Hims & Hers Shareholders Approve All Proposals at 2025 Annual Meeting

Hims & Hers Health, Inc. held its Annual Meeting of Stockholders on June 12, 2025. Shareholders approved all three proposals, including the election of eight directors to serve until the next annual meeting. Each nominee received strong majority support, with Deborah Autor, Kare Schultz, and Andrea Perez among those re-elected with the highest approval.

KPMG LLP was ratified as the company’s independent auditor for the fiscal year ending December 31, 2025. Additionally, shareholders gave advisory approval to the company’s executive compensation plan, signaling support for current leadership and compensation practices. Voting included both Class A and Class V common stock, with combined voting power based on their respective vote weights.

💬

M

ME NEWS 06-18-25

Hims & Hers Issues $1.0 Billion in Zero-Coupon Convertible Notes Due 2030, Accompanied by Capped Call Transactions

Hims & Hers Health, Inc. has completed the issuance of $1.0 billion in principal amount of 0.00% Convertible Senior Notes due 2030, following full exercise of an over-allotment option. The privately placed offering, conducted under Rule 144A, was finalized on May 13, 2025, with the notes governed by an indenture with U.S. Bank Trust Company.

These senior unsecured notes mature on May 15, 2030, and do not bear interest. They are convertible into Class A common stock at an initial price of approximately $70.67 per share, with a maximum potential conversion rate of 19.4552 shares per $1,000 of principal. Redemption and conversion rights may be triggered by specified events, including “Make-Whole Fundamental Changes” or corporate reorganizations.

To offset dilution from potential conversions, Hims & Hers also entered into capped call transactions with several financial institutions. These cover the same number of shares underlying the notes and carry a cap price of $89.95, representing a 75% premium over the share price at pricing. The capped call transactions cost the company approximately $47.8 million.

💬

M

ME NEWS 05-13-25

NYSE:HIMSFollow

Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

NYSE:HIMS